Clinical Trial Update: Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

View source ↗

Summary

This clinical trial update reports real-world outcomes for ALK-positive early-stage non-small cell lung cancer patients treated with adjuvant alectinib after su…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alecensa (alectinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Carcinoma, Non-Small-Cell Lung | Status: RECRUITING